Badar, T., Kantarjian, H. M., Ravandi, F., Jabbour, E., Borthakur, G., Cortes, J. E., . . . Verstovsek, S. (2015). Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res.
Citação norma ChicagoBadar, Talha, et al. "Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients With High-risk Primary Myelofibrosis and Myeloproliferative Neoplasm in Accelerated or Blastic/acute Myeloid Leukemia Phase." Leuk Res 2015.
MLA citiranjeBadar, Talha, et al. "Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients With High-risk Primary Myelofibrosis and Myeloproliferative Neoplasm in Accelerated or Blastic/acute Myeloid Leukemia Phase." Leuk Res 2015.